tiprankstipranks

Jacobio Pharmaceuticals Advances Cancer Drug Pipeline with Strategic Licensing and Trials

Story Highlights
  • Jacobio Pharmaceuticals focuses on innovative cancer treatments, particularly in the RAS space.
  • The company progresses its drug pipeline with key trials and a significant licensing deal in China.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Jacobio Pharmaceuticals Advances Cancer Drug Pipeline with Strategic Licensing and Trials

Confident Investing Starts Here:

Jacobio Pharmaceuticals Group Co., Ltd. ( (HK:1167) ) has issued an announcement.

Jacobio Pharmaceuticals has announced significant progress in its drug development pipeline, including the submission of a New Drug Application for glecirasib for second-line NSCLC in China and the initiation of pivotal trials for other cancer types. The company has licensed the Greater China rights of glecirasib and sitneprotafib to Allist, securing a deal worth RMB900 million plus royalties, and launched first-in-human trials in the U.S. and China, reinforcing its position as a leader in the global R&D biotech space.

More about Jacobio Pharmaceuticals Group Co., Ltd.

Jacobio Pharmaceuticals Group Co., Ltd. is a biotech company focused on innovation-driven global research and development, particularly in the RAS space. The company specializes in developing treatments for various cancers, including non-small cell lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC), and it has a strong market focus on China and the U.S.

YTD Price Performance: 122.05%

Average Trading Volume: 4,603,490

Technical Sentiment Consensus Rating: Sell

Current Market Cap: HK$2.23B

For detailed information about 1167 stock, go to TipRanks’ Stock Analysis page.

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.

Report an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1